All Title Author
Keywords Abstract

PLOS ONE  2014 

Impact of Acetazolamide and CPAP on Cortical Activity in Obstructive Sleep Apnea Patients

DOI: 10.1371/journal.pone.0093931

Full-Text   Cite this paper   Add to My Lib


Study Objectives 1) To investigate the impact of acetazolamide, a drug commonly prescribed for altitude sickness, on cortical oscillations in patients with obstructive sleep apnea syndrome (OSAS). 2) To examine alterations in the sleep EEG after short-term discontinuation of continuous positive airway pressure (CPAP) therapy. Design Data from two double-blind, placebo-controlled randomized cross-over design studies were analyzed. Setting Polysomnographic recordings in sleep laboratory at 490 m and at moderate altitudes in the Swiss Alps: 1630 or 1860 m and 2590 m. Patients Study 1: 39 OSAS patients. Study 2: 41 OSAS patients. Interventions Study 1: OSAS patients withdrawn from treatment with CPAP. Study 2: OSAS patients treated with autoCPAP. Treatment with acetazolamide (500–750 mg) or placebo at moderate altitudes. Measurements and Results An evening dose of 500 mg acetazolamide reduced slow-wave activity (SWA; approximately 10%) and increased spindle activity (approximately 10%) during non-REM sleep. In addition, alpha activity during wake after lights out was increased. An evening dose of 250 mg did not affect these cortical oscillations. Discontinuation of CPAP therapy revealed a reduction in SWA (5–10%) and increase in beta activity (approximately 25%). Conclusions The higher evening dose of 500 mg acetazolamide showed the “spectral fingerprint” of Benzodiazepines, while 250 mg acetazolamide had no impact on cortical oscillations. However, both doses had beneficial effects on oxygen saturation and sleep quality.


[1]  Ho LM, Brass SD (2011) Obstructive sleep apnea. Neurology International 3: 60–67. doi: 10.4081/ni.2011.e15
[2]  Punjabi NM (2008) The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 5: 136–143. doi: 10.1513/pats.200709-155mg
[3]  Latshang TD, Nussbaumer-Ochsner Y, Henn RM, Ulrich S, Lo Cascio CM, et al. (2012) Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. Jama 308: 2390–2398. doi: 10.1001/jama.2012.94847
[4]  McArdle N, Douglas NJ (2001) Effect of continuous positive airway pressure on sleep architecture in the sleep apnea-hypopnea syndrome: a randomized controlled trial. Am J Respir Crit Care Med 164: 1459–1463. doi: 10.1164/ajrccm.164.8.2008146
[5]  Engleman HM, Martin SE, Deary IJ, Douglas NJ (1997) Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Thorax 52: 114–119. doi: 10.1136/thx.52.2.114
[6]  Morisson F, Decary A, Petit D, Lavigne G, Malo J, et al. (2001) Daytime sleepiness and EEG spectral analysis in apneic patients before and after treatment with continuous positive airway pressure. Chest 119: 45–52. doi: 10.1378/chest.119.1.45
[7]  Morisson F, Lavigne G, Petit D, Nielsen T, Malo J, et al. (1998) Spectral analysis of wakefulness and REM sleep EEG in patients with sleep apnoea syndrome. Eur Respir J 11: 1135–1140. doi: 10.1183/09031936.98.11051135
[8]  Dingli K, Assimakopoulos T, Fietze I, Witt C, Wraith PK, et al. (2002) Electroencephalographic spectral analysis: detection of cortical activity changes in sleep apnoea patients. Eur Respir J 20: 1246–1253. doi: 10.1183/09031936.02.00288202
[9]  Guilleminault C, Do Kim Y, Chowdhuri S, Horita M, Ohayon M, et al. (2001) Sleep and daytime sleepiness in upper airway resistance syndrome compared to obstructive sleep apnoea syndrome. Eur Respir J 17: 838–847. doi: 10.1183/09031936.01.17508380
[10]  Himanen SL, Virkkala J, Huupponen E, Hasan J (2003) Spindle frequency remains slow in sleep apnea patients throughout the night. Sleep Med 4: 229–234. doi: 10.1016/s1389-9457(02)00239-3
[11]  Ondze B, Espa F, Dauvilliers Y, Billiard M, Besset A (2003) Sleep architecture, slow wave activity and sleep spindles in mild sleep disordered breathing. Clin Neurophysiol 114: 867–874. doi: 10.1016/s1388-2457(02)00389-9
[12]  Heinzer R, Gaudreau H, Decary A, Sforza E, Petit D, et al. (2001) Slow-wave activity in sleep apnea patients before and after continuous positive airway pressure treatment: contribution to daytime sleepiness. Chest 119: 1807–1813. doi: 10.1378/chest.119.6.1807
[13]  Hoshikawa M, Uchida S, Sugo T, Kumai Y, Hanai Y, et al. (2007) Changes in sleep quality of athletes under normobaric hypoxia equivalent to 2,000-m altitude: a polysomnographic study. J Appl Physiol 103: 2005–2011. doi: 10.1152/japplphysiol.00315.2007
[14]  Johnson PL, Edwards N, Burgess KR, Sullivan CE (2010) Sleep architecture changes during a trek from 1400 to 5000 m in the Nepal Himalaya. J Sleep Res 19: 148–156. doi: 10.1111/j.1365-2869.2009.00745.x
[15]  Latshang TD, Lo Cascio CM, St?whas A, Grimm M, Stadelmann K, et al.. (2013) Are nocturnal breathing, sleep and cognitive performance impaired at moderate altitude (1630–2590 m)? A randomized trial. Sleep: in press.
[16]  Nussbaumer-Ochsner Y, Ursprung J, Siebenmann C, Maggiorini M, Bloch KE (2012) Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing. Sleep 35: 419–423. doi: 10.5665/sleep.1708
[17]  AASM Task Force (1999) Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 22: 667–689.
[18]  Caruana-Montaldo B, Gleeson K, Zwillich CW (2000) The control of breathing in clinical practice. Chest 117: 205–225. doi: 10.1378/chest.117.1.205
[19]  Leaf DE, Goldfarb DS (2007) Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J Appl Physiol 102: 1313–1322. doi: 10.1152/japplphysiol.01572.2005
[20]  Ritchie ND, Baggott AV, Andrew Todd WT (2012) Acetazolamide for the prevention of acute mountain sickness—a systematic review and meta-analysis. J Travel Med 19: 298–307. doi: 10.1111/j.1708-8305.2012.00629.x
[21]  West JB, Schoene RB, Milledge JS (2007) Acute mountain sickness. High Altitude Medicine and Physiology. 4th ed: Hodder Arnold. pp. 251–269.
[22]  Nussbaumer-Ochsner Y, Latshang TD, Ulrich S, Kohler M, Thurnheer R, et al. (2012) Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest 141: 131–138. doi: 10.1378/chest.11-0375
[23]  Nussbaumer-Ochsner Y, Schuepfer N, Ulrich S, Bloch KE (2010) Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial. Thorax 65: 429–435. doi: 10.1136/thx.2009.125849
[24]  Fischer R, Lang SM, Leitl M, Thiere M, Steiner U, et al. (2004) Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 23: 47–52. doi: 10.1183/09031936.03.00113102
[25]  Staley KJ (2002) Diuretics as Antiepileptic Drugs: Should We Go with the Flow? Epilepsy Curr 2: 35–38. doi: 10.1046/j.1535-7597.2002.00018.x
[26]  Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda, Md: National Institutes of Health.
[27]  Stadelmann K, Latshang TD, Lo Cascio CM, Tesler N, Stoewhas AC, et al. (2013) Quantitative changes in the sleep EEG at moderate altitude (1630 m and 2590 m). PLoS One 8: e76945. doi: 10.1371/journal.pone.0076945
[28]  Gottselig JM, Bassetti CL, Achermann P (2002) Power and coherence of sleep spindle frequency activity following hemispheric stroke. Brain 125: 373–383. doi: 10.1093/brain/awf021
[29]  Javaheri S (2006) Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 173: 234–237. doi: 10.1164/rccm.200507-1035oc
[30]  Ritchie ND, Baggott AV, Andrew Todd WT (2012) Acetazolamide for the prevention of acute mountain sickness - A systematic review and meta-analysis. J Travel Med 19: 298–307. doi: 10.1111/j.1708-8305.2012.00629.x
[31]  E. K. Jackson (2006) Drugs Affecting Renal and Cardiovascular Function. In: L. L Brunton, J. S Lazo, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics.11th ed. New York: Mc Graw-Hill Medical Publishing Division. pp. 297–315.
[32]  Aeschbach D, Cajochen C, Tobler I, Dijk DJ, Borbely AA (1994) Sleep in a sitting position: effect of triazolam on sleep stages and EEG power spectra. Psychopharmacology (Berl) 114: 209–214. doi: 10.1007/bf02244838
[33]  Borbély AA, Mattmann P, Loepfe M, Fellmann I, Gerne M, et al. (1983) A single dose of benzodiazepine hypnotics alters the sleep EEG in the subsequent drug-free night. Eur J Pharmacol 89: 157–161. doi: 10.1016/0014-2999(83)90622-2
[34]  Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D (1985) Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 4: 189–194. doi: 10.1016/0014-2999(83)90622-2
[35]  Brunner DP, Dijk DJ, Munch M, Borbely AA (1991) Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology (Berl) 104: 1–5. doi: 10.1007/bf02244546
[36]  Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42 Suppl 38–12. doi: 10.1046/j.1528-1157.2001.042suppl.3008.x
[37]  Staley KJ, Soldo BL, Proctor WR (1995) Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 269: 977–981. doi: 10.1126/science.7638623
[38]  Fietze I, Quispe-Bravo S, Hansch T, Rottig J, Baumann G, et al. (1997) Arousals and sleep stages in patients with obstructive sleep apnoea syndrome: Changes under nCPAP treatment. J Sleep Res 6: 128–133. doi: 10.1046/j.1365-2869.1997.00029.x
[39]  Engleman HM, Cheshire KE, Deary IJ, Douglas NJ (1993) Daytime sleepiness, cognitive performance and mood after continuous positive airway pressure for the sleep apnoea/hypopnoea syndrome. Thorax 48: 911–914. doi: 10.1136/thx.48.9.911
[40]  Stadelmann K, Latshang TD, Tarokh L, Lo Cascio CM, Tesler N, et al.. (2014) Sleep respiratory disturbances and arousals at moderate altitude have overlapping EEG spectral signatures. J Sleep Res (in press).
[41]  Borbély AA (1982) A two process model of sleep regulation. Hum Neurobiol 1: 195–204.
[42]  Banks S, Dinges DF (2007) Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 3: 519–528.
[43]  Dijk DJ, Groeger JA, Stanley N, Deacon S (2010) Age-related reduction in daytime sleep propensity and nocturnal slow wave sleep. Sleep 33: 211–223.


comments powered by Disqus